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ABSTRACT
Background: Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women
in Canada. Essiac (Resperin™ Canada Limited, Waterloo, Ontario, Canada), a blend of at least four herbs (bur-
dock root [Arctium lappa], Indian rhubarb [Rheum palmatum], sheep sorrel [Rumex acetosella], and the inner
bark of slippery elm [Ulmus fulva or U. rubra]), has become one of the more popular herbal remedies for breast-
cancer treatment, secondary prevention, improving quality of life, and controlling negative side-effects of con-
ventional breast-cancer treatment.
Objectives: Our primary objective was to determine the difference in health-related quality of life (HR-
QOL), as assessed by the Functional Assessment of Cancer Therapy Breast Cancer Version, between women
who are new Essiac users (since breast cancer diagnosis) and those who have never used Essiac. Secondary
endpoints included differences in depression, anxiety, fatigue, rate of adverse events, and prevalence of com-
plications or benefits associated with Essiac during standard breast-cancer treatment. Additionally, we described
the pattern of use of Essiac in this cohort of women.
Methods: We performed a retrospective cohort study in 510 women, randomly chosen from the Ontario Can-
cer Tumour Registry, with a diagnosis of primary breast cancer in 2003.
Results: With the exception changes in a Physical well-being subscale and a relationship with doctor sub-
scale, Essiac did not have a significant effect on HR-QOL or mood states. Even for Physical well-being and
relationship with doctor, Essiac seemed to have a negative effect, with Essiac users doing worse than the non-
Essiac users. This might be attributed to the fact that the group of users comprised younger women with more
advanced stages of breast cancer, and both of these subgroups of patients have been shown to be at a signifi-
cantly increased risk for negative mood states and/or a decreased sense of well-being. The women were taking
low doses (total daily dose 43.6  30.8 mL) of Essiac that corresponded to the label directions found on most
Essiac products. Friends were the most common source of information, and most women were taking Essiac
to boost their immune systems or increase their chances of survival. Only 2 women reported minor adverse
events, whereas numerous women reported beneficial effects of Essiac.
Conclusions: Essiac does not appear to improve HR-QOL or mood states. Future studies are needed to de-
termine whether other clinical outcomes, such as cancer reoccurrence, are affected by Essiac.
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INTRODUCTION
The importance of breast cancer in women as a publichealth problem is well-recognized worldwide.1,2 In
Canadian women, breast cancer is the most common neo-
plasm, with a lifetime risk calculated as 1 in 9.3 As a result
of mammographic screening, early detection of disease, and
improved therapies, the rate of breast cancer-mortality is
steadily declining in Canada.3 Nonetheless, in 2005, it is es-
timated that 21,600 women were diagnosed and 5300
women died of this disease.3 Furthermore, Ontario had the
highest incidence of breast cancer cases in Canada, with
8200 of the 21,600 new cases in 2005.3
Health-related quality of life (HR-QOL) is becoming an
increasingly important endpoint for assessing treatment and
management in breast cancer.4,5 Conventional endpoints for
evaluating cancer treatments include disease-free survival
time, tumor response, and overall survival. Over time, how-
ever, it has become evident that these endpoints alone are
not adequate to make informed decisions about treatment
options for breast cancer. Measurements of HR-QOL are
recognized as comprising a more complete assessment of
patients’ physical, emotional, mental, and spiritual well-be-
ing.5,6 Additionally, HR-QOL measures may provide prog-
nostic information independent of other parameters such as
disease severity,6,7 and some scales have been found to be
significantly associated with patients’ survival.4 Further-
more, HR-QOL scales help to measure the effects of the
severity as well as the duration of toxic side effects from
treatment (e.g., neuropathy) augmenting information re-
ceived from conventional toxicity scales.6
There have been numerous recent surveys of comple-
mentary and alternative medicine (CAM) use among pa-
tients with breast cancer in the United States, Britain, and
Canada.8–13 Survey results among patients with breast can-
cer find that prevalence of CAM use ranges from 16.5% to
84%.8–13 In a study examining the prevalence of CAM use
among Ontario women with breast cancer, 67% of the
women surveyed used some form of alternative therapies.
Of these women, almost 15% used Essiac (Resperin™
Canada Limited, Waterloo, Ontario, Canada), an herbal rem-
edy, which was the second most commonly used natural
health product after green tea (Camellia sinensis) (17.3%).8
Moreover, in the United States, a survey of Flor-Essence®
(an Essiac formula, Flora Manufacturing and Distributing,
Burnaby, British Columbia, Canada) users found that, of
5051 respondents, 22% had breast cancer.14,15 An estimate
of annual U.S. Essiac sales exceeded $8 million in 2001.14
An international study conducted by the Canadian Cancer
Society’s Cancer Information Services (CIS) to identify the
information needs of those who called CIS requesting in-
formation on CAM found that, of the 109 callers, the ma-
jority were women (80%), most of their questions concerned
the safety and/or effectiveness of natural health products,
and breast cancer was the most common type of cancer
queried (22%). Of these queries, the top CAM topics most
often asked about were 714X (N  17) and Essiac (N  16).
The study author concluded that more cancer-specific in-
formation on Essiac use in breast cancer is needed.16
Essiac has been used in Canada for more than 70 years.17
The recipe for Essiac is said to have been given to a nurse,
Rene Caisse, by 1 of her patients who reportedly learned of
the mixture from an Ojibwa healer and claimed it cured her
breast cancer. Beginning in the 1920s, Caisse administered
Essiac to hundreds of patients with cancer for more than 40
years.17
The original Essiac recipe contained four herbs: burdock
root (Arctium lappa); Indian rhubarb (Rheum palmatum);
sheep sorrel (Rumex acetosella); and the inner bark of slip-
pery elm (Ulmus fulva or U. rubra). Caisse administered one
of the herbs by injection and the others as a tea. By 1938,
however, concerns about the use of Essiac led to an inves-
tigation by the Cancer Commission.17 Evidence of 1 report
of death and 1 report of toxicity after Essiac tea injec-
tions18,19 led to the practice of injecting Essiac herbs being
deemed unsafe because of a potential for systemic toxicity.
Between 1959 and 1978, Caisse worked in collaboration
with an American physician, Charles Brusch, M.D., 
adding four additional herbs to the original recipe: water-
cress (Nasturtium officinale); blessed thistle (Cnicus bene-
dictus); red clover (Trifolium pretense); and kelp (Laminaria
digitata). This new mixture did not require injection and
could thus be used at home. Essiac became available to con-
sumers in both the 4- and 8-herb varieties in the 1990s. To-
day, more than 40 different Essiac formulas are available
throughout North America, Australia, and the United King-
dom.14
Despite the widespread use of and interest in Essiac
among women with breast cancer, there are no published
clinical trials and very little animal or in vitro work, most
of which is also unpublished. Available Essiac research is
difficult to assess because of a lack of information about
methodology, differences in Essiac formulations studied,
and variance in the experimental animal models in in vivo
studies. Anecdotal reports indicate that Essiac may be of
benefit in the treatment of cancer, but such reports are lim-
ited by their subjective and qualitative nature. Much of the
research conducted is thus restricted by poor design, small
sample size, lack of control, unclear product stability and/or
consistency, and lack of physician cooperation. Given the
limitations to date, a well-designed, population-based study
on the effects of Essiac is warranted.
The primary objective of our study was to determine the
difference in HR-QOL as assessed by the Functional As-
sessment of Cancer Therapy Breast Cancer Version (FACT-
B) between women who are new Essiac users since breast
cancer diagnosis and those who have never used Essiac. Sec-
ondarily, the study was designed to determine the effect of
Essiac in women with a primary diagnosis of breast cancer
who are new Essiac users since breast cancer diagnosis com-
pared to women who have never used Essiac on the fol-
lowing secondary endpoints:
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1. Depression, anxiety, and fatigue as measured by the Pro-
file of Mood Syndromes (POMS)
2. Prevalence of complications during standard breast can-
cer treatment (chemotherapy radiation, surgery, and hor-
monal therapy) as determined by self-report
3. Prevalence of any adverse events (e.g., rash, stomach up-
set) occurring after standard therapy as determined by
self-report.
The third objective was to describe Essiac use in women
with a primary diagnosis of breast cancer including:
1. Brand used
2. Duration and continuity of use (e.g., used for 3 years but
stopped for 1 month during treatment)
3. Frequency and schedule of use (e.g., 1 cup, three times
per day)
4. Method of preparation (if applicable)
5. When use was initiated and stopped 
6. Adverse effects associated with use.
MATERIALS AND METHODS
This was a retrospective study design examining the ef-
fect of Essiac on women with breast cancer. Women who
were 18 years or older, had been diagnosed with primary
breast cancer (positive pathology report) between 2001 and
2003, and able to read and write in English, were eligible
to participate in the study. Any woman who had been diag-
nosed with any type of cancer prior to a diagnosis of breast
cancer or who had previously used Essiac was excluded
from the study.
The sample was a computer-generated random selection
from the Ontario Cancer Registry of those women diagnosed
with primary breast cancer in 2003 (N  2541), subject to
the requirements and protocols of the Registry. We attempted
to obtain permission to contact each patient and confirma-
tion of current mailing address from her oncologist follow-
ing the Registry’s protocol. Oncologists who did not respond
to a letter requesting permission to contact their patients re-
ceived up to three follow-up telephone calls. In total, we re-
ceived responses regarding 1453 patients (57.2%) and per-
mission to contact 952 patients (37.5%); however, mailing
addresses were only available for 877 (34.5%) (Fig. 1).
A modified Dillman20 protocol was used to survey the
random sample of patients with breast cancer selected from
the Ontario Cancer Registry. A cover letter, questionnaire,
and stamped, self-addressed return envelope were mailed to
each woman in the entire sample (N  877). Failure to re-
spond to the original and two follow-up mailings was con-
sidered a refusal to participate in the study.
The survey instruments
Each woman received a packet that contained 5 surveys
including (1) the FACT-B,21 which is a 44-item self-ad-
ministered, 5-point Likert scale for evaluating functional im-
pairment and the perceived effect of that impairment on
quality of life; (2) POMS,22 which is a measure of patient
distress; (3) Yale Social Support Index (YALE),23 which is
used to assess the amount and quality of social contact and
support; (4) Patterns and Use of Essiac, which measures
whether a study participant has used Essiac, which brand,
timeline, amount, and adverse effects; and (5) Prevalence of
Use of Complementary/Alternative Therapies, which is
based on a survey developed by Yates et al.24 and modified
to be relevant to Canadians.25 At the end of the prevalence
survey, participants were also asked about any conventional
medical treatments for their breast cancer, stage of disease
at diagnosis, current disease state, and demographic data.
Statistical analysis
Clinical and sociodemographic characteristics of Essiac
users and non-Essiac users were compared using an inde-
pendent samples t-test and a chi-square test, for continuous
and categoric variables, respectively. For categoric mea-
surements, the chi-square test was replaced by Fisher’s ex-
act test, whenever the observed percentage in any cross-
classified category fell below 10. Frequencies, percentages,
and means were calculated to describe the pattern of Essiac
use, who recommended Essiac, and reasons for Essiac use.
Summary score for each subscale of FACT-B and POMS
was constructed by first computing an itemwise average by
dividing the total score by the number of items responded and
then multiplying this average by the total number of items in
the subscale. The scores for individuals who responded to less
than 75% of the items were considered to be missing. Also,
although each subscale has both positively and negatively
framed items, for ease of comparison and interpretation, we
reverse coded all positively framed questions, so that a higher
average score for any scale signified a worse state.
For continuous variables (FACT-B, POMS), initial ex-
ploratory analysis was carried out using independent sam-
ples t-tests comparing women who used Essiac to nonusers.
Subsequently, the subscales of FACT-B and POMS were
used as continuous outcomes in a multiple-regression frame-
work. For these models, Essiac use (yes/no) was entered into
the equation as an independent variable simultaneously
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FIG. 1. Derivation of the sample.
along with age, marital status, income, educational status,
stage of disease, months since diagnosis, and number of in-
dividuals in self-reported social network as reported by the
YALE questionnaire to determine their effects on mood
states and HR-QOL. The variables entered into the regres-
sion models were chosen primarily because of the general
consensus among researchers in this area about their poten-
tial effects on mood states or HR-QOL outcomes. In all the
multiple regression models with FACT-B and POMS sub-
scales as outcomes, the residuals demonstrated substantial
departure from normality, thereby rendering the linear model
an improper fit. We conducted systematic analyses with
transformed models using Box-Cox family of power trans-
formations,26 and found that a square-root transformation of
the outcomes worked well in linearizing the relationship. All
the regression results we present in this article are thus for
the square-root transformed models.
We found it difficult to treat the FACT-B subscale “re-
lationship with doctor” as a continuous outcome. This was
primarily because the subscale is based only on two ques-
tions, with many respondents answering 0 to both questions
(50%). Thus we treated this single variable in a logistic
regression framework (score  0 or positive) with the same
predictors as described above.
Data were input into SPSS Windows version 12 (SPSS,
Chicago, IL), then manipulated and analyzed using both
SPSS and SAS version 9.1. (SAS Institute Inc, Cary NC).
A p-value of less than 0.05 was considered to be statisti-
cally significant.
The study was designed to have 80% power to detect a
treatment difference of 7 points in FACT-G, based on pub-
lished standard deviations of 13.9–15.9 in similar popula-
tions with a mean of 67–91,27 assuming a two-sided  level
of 0.05. This design required n  120 per treatment group.
RESULTS
A total of 541 of surveys were returned. Sixteen (16) fam-
ilies contacted us to inform us that the respondents had died,
and 57 envelopes were returned marked “address unknown.”
Thus, our final response rate was 63% (541/(877  16)). Of
the 541 surveys, 31 were deemed to be ineligible, primarily
because the respondents’ dates of diagnosis were before
2003, leaving 510 eligible participants. A total of 41 re-
spondents (8%) reported using Essiac, of which 32 (6.2%)
reported using Essiac for treating their breast cancer.
Sociodemographic and clinical characteristics
We present the sociodemographic and clinical character-
istics of women in the study by Essiac use in Table 1.
Women who used Essiac were significantly younger (55 ver-
sus 62; p  0.005) and more likely to be married (p  0.04).
In addition, Essiac users were diagnosed with breast cancer
at a later stage (p  0.03) and were more likely to have re-
ceived chemotherapy (p  0.001). There were no significant
differences in ethnicity, educational level, total annual
household income, rates of estrogen or progesterone posi-
tive cancers, or other-breast cancer treatment options (e.g.,
surgery) between women who used Essiac and nonusers. 
Reasons and patterns of Essiac
Women listed a variety of reasons for using Essiac. The
three most common reasons for taking Essiac were “to boost
my immune system” (N  22/73%), “to improve my
chances of survival” (N  22/73%), and “to prevent a re-
currence of cancer” (N  19/63%). Most women had a
friend who recommended Essiac to them (N  13/42%).
Other women self-referred (N  6/19%), had family mem-
bers (N  5/16%), or naturopathic physicians (N  6/19%)
recommend Essiac to them. Only 1 woman decided to take
Essiac from information obtained from the media.
Two thirds of the women using Essiac for breast cancer
purchased an Essiac product. Although there are more than
40 brands available commercially in Ontario, the majority
of women purchased the Essiac (N  18/75%) brand, which
contains the 4-herb blend, with only a few women purchas-
ing Flor-Essence (N  4/17%), which contains the 8-herb
blend, or other miscellaneous brands (N  3/13%). A quar-
ter of the women bought multiple brands of Essiac products
(N  6/26%). A third of women either made the Essiac tea
themselves (N  1/3%) or had someone else make it for
them (N  9/31%) (e.g., a family member or nurse).
The majority of women took Essiac either once or twice
per day (N  26/93%), with a very small minority taking it
three times per day (N  2/7%). The average daily dose of
Essiac was 43.6 ( 30.8) and ranged from 12 to 114 mL
per day. The mean length of Essiac use was 11.1 ( 8.9)
months, but ranged anywhere from 1 to 28 months.
Adverse events and interactions with breast 
cancer treatment
Only two women reported having adverse effect from tak-
ing Essiac, and both of these were complaints of nausea and
an unpleasant aftertaste. No women reported that Essiac in-
terfered with their breast-cancer treatment. In contrast, 6
women reported experiencing positive interactions between
Essiac and their treatment for breast cancer. Positive inter-
actions reported included a decrease in negative side-effects,
increased effectiveness, decreased fatigue, and diminished
nausea and vomiting from breast cancer treatment. In addi-
tion, women also perceived that Essiac allowed them to take
their treatments in a timely fashion and that Essiac supported
their immune systems during treatments.
Quality of life and mood states
We found that Essiac users and nonusers were significantly
different with respect to the FACT-B physical well-being
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scale, both in the unadjusted analysis (Table 2; p value 
0.02) and in the adjusted analysis (Table 2; p value  0.02).
Women who used Essiac reported worse physical well-being
than the nonusers. We obtained a similar result for the rela-
tionship with doctor subscale. In a logistic regression analy-
sis, the Essiac user group was found to be marginally worse
with respect to patient–doctor relationship than the nonusers
with an estimated odds ratio of 0.40 (p-value  0.047, 95%
C.I. for odds ratio: [0.16, 0.988]). For all other FACT-B sub-
scales, no statistically significant difference was obtained be-
tween the users and nonusers. In all cases, however, women
who used Essiac consistently had higher scores, indicating
more severe symptoms than nonusers.
Table 3 indicates the association of other potential con-
founders with FACT-B. Age turned out to have significant
associations with physical and emotional well-being, with
older women appearing to cope better than the younger ones.
Stage of cancer also had significant associations with these
two outcomes, with patients diagnosed with more advanced
stage faring worse. Income level has a significant associa-
tion with social well-being only. For all subscales, however,
the women in the lower-income groups scored higher
(worse) on average. The variable “number of supports” had
the strongest association with the FACT-B scale because it
was negatively associated with all the subscales, indicating
a large impact of social support on the HR-QOL. Education,
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TABLE 1. SOCIODEMOGRAPHICS AND CLINICAL CHARACTERISTICS
Essiac nonusers Essiac users
Characteristics (N  469)a (N  41)a
Age, mean (STD), yearsb 61.6 (13.3) 55.4 (12.7)
Ethnicity, no. (%)
North American 295 (63) 22 (54)
European 74 (16) 7 (17)
Multiethnic 37 (8) 5 (12)
Otherc 35 (7) 4 (10)
Education, no. (%)
Completed high school 185 (39) 17 (41)
Completed college/university degree 184 (39) 19 (46)
Completed grade 8 67 (14) 1 (2)
Less than grade 8 17 (4) 2 (5)
Income,d no. (%)
$20,000 83 (18) 7 (17)
$20,000–$30,999 83 (18) 5 (12)
$40,000–$59,999 84 (18) 5 (12)
$60,000–$79,999 54 (11) 4 (10)
$80,000 or more 85 (18) 13 (32)
Marital status, no. (%)e
Married/common-law 295 (63) 32 (78)
Widowed 83 (18) 1 (2)
Divorced/separated 59 (13) 5 (12)
Never married 24 (5) 2 (5)
Stage at diagnosis, no. (%)e
Stage I 207 (44) 12 (29)
Stage II 109 (23) 15 (37)
Stage III 57 (12) 6 (15)
Stage IV 5 (1) 2 (5)
Treatments for breast cancer, no. (%)
Surgery 429 (91) 36 (88)
Radiation 312 (67) 31 (76)
Tamoxifen 245 (52) 19 (46)
Chemotherapyb 198 (42) 28 (68)
Breast cancer receptor status, no. (%)
Estrogen positive 217 (46) 23 (56)
Progesterone positive 57 (12) 6 (15)
Months since diagnosis, mean (SD) 27.3 (4.65) 27.6 (5.41)
aNumbers may not add up to 469 for nonusers and 41 for Essiac users because of nonresponse.
bp value  0.01.
cSouth Asian, Filipino, Arab/Middle Eastern, Chinese, Japanese, African, Caribbean, Aboriginal, Latin American, Unknown.
dTotal household income in Canadian dollars.
ep value  0.05.
STD, standard deviation.
marital status, and months since diagnosis had no signifi-
cant association with any of the subscales.
We also found no significant difference in either unad-
justed or adjusted analyses for any of the six subscales of
the POMS between women who used Essiac and women
who had never used Essiac (Table 4). In general, Essiac users
also had higher mean scores on four of the POMS subscales
indicating more “mood” disturbances, such as anxiety. Table
5 shows the effect of various covariates on POMS. Of these,
age seemed to have a significant association with most of
the subscales considered. For example, older women ap-
peared to be significantly less anxious, depressed, confused,
angry, and fatigued compared to the younger ones on aver-
age. As for the FACT-B QOL scales, number of people in
women’s support network also has a large positive impact
on the mood states. Both education level and stage of dis-
ease have mild impact on the mood states, each being sig-
nificantly associated with one of the scales. On the other
hand, income level seems to have a modest impact, with
women at a lower income category generally at a worse state
of mood than their wealthier counterparts. Once again, sim-
ilar to the FACT-B QOL measures, marital status and
months since diagnosis had no association with the mood
states.
DISCUSSION
We found that 8.1% of Ontario women with breast can-
cer take Essiac and, of these women, approximately 75%
use Essiac for breast cancer. It is unknown why the 25% of
women who were not using Essiac specifically for their
breast cancer were using the product. The overall percent-
age of Essiac users is similar (8.1% vs. 9%) to a previous
survey conducted by Boon8 in a cohort of women drawn
from the Ontario Cancer Registry and diagnosed with breast
cancer in 1994 or 1995. In addition, the majority of women
using Essiac in our study bought either Essiac or Flor-
Essence brands and appeared to be taking doses recom-
mended on Essiac or Flor-Essence labels.
Our study indicated that the doses, frequencies, and
brands of Essiac used by the women in this study did not
have any effect on either disease-specific quality of life, as
measured by the FACT-B, or various mood states including
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TABLE 2. RESULTS OF UNADJUSTED AND ADJUSTED ANALYSES FOR FACT-B
Nonusers Essiac users
Subscales mean (STD) mean (STD) p value*1 Adjusted p value*3
Physical well-being 4.0 (4.3) 5.7 (5.0) 0.02 0.02
Social well-being 4.5 (4.7) 4.5 (4.7) 0.85 0.88
Emotional well-being 4.5 (4.1) 5.4 (4.4) 0.18 0.23
Functional well-being 6.4 (5.4) 6.9 (6.3) 0.57 0.83
Relationship with doctor 1.3 (1.7) 1.5 (1.7) 0.35*2 0.05
*p values (1) are based on independent sample t-test comparing the mean of Essiac users to nonusers except for relationship with
doctor, which is (2) presented as Fisher’s Exact test comparing scores of 1 versus 0; (3) adjusted analyses are based on multiple linear
regressions with the well-being subscales as outcomes, adjusted for age, marital status, income, educational status, stage of disease,
months since breast cancer diagnosis and number of individuals in self-reported social network as reported by the Yale Social Support
Index. For relationship with doctor, the adjusted analysis is based on logistic regression.
FACT-B, Functional Assessment of Cancer Therapy Breast Cancer Version; STD, standard deviation.
TABLE 3. SUMMARY OF REGRESSION RESULTS OF FACT-B SUBSCALES
Stage at Number of
Subscales Essiac use Age diagnosis supports Income
Physical well-beinga1 0.50 (0.22)* 0.02 (0.01)** 0.18 (0.08)* 0.02 (0.01)* 0.10 (0.05)
Social well-beinga1 0.04 (0.26) 0.00 (0.01) 0.07 (0.09) 0.05 (0.01)** 0.15 (0.06)*
Emotional well-beinga1 0.25 (0.21) 0.02 (0.01)** 0.21 (0.08)** 0.02 (0.01)* 0.03 (0.05)
Functional well-beinga1 0.17 (0.24) 0.00 (0.01) 0.11 (0.09) 0.02 (0.01)* 0.11 (0.06)
Relationship with doctora2 0.40 (0.18)* 1.00 (0.01) 1.02 (0.15) 0.96 (0.02)* 1.05 (0.11)
aTable entries are (1) regression coefficients with standard errors (SE) in parentheses; well-being outcomes are square root of the
subscale scores obtained from the survey for the well-being subscales, (2) and Odds Ratio (SE) for relationship with doctor, relation-
ship with doctor is a dichotomous outcome; all regression models are additionally adjusted for marriage status (currently married or
not), education level, and months since diagnosis. Negative regression coefficients indicate that the lower the value (e.g., lower age, in-
come) the worse the woman’s well-being; the opposite relationship is also true (e.g., lower stage/severity at time of diagnosis the bet-
ter the woman’s well-being).
*p-value  0.05.
**p-value  0.01.
depression and anxiety. This was despite the finding that Es-
siac users were significantly worse than regarding physical
well-being compared to nonusers. We propose that Essiac
use is just a marker of physical distress and not its cause.
Instead our data appear to indicate that younger women with
more advanced disease and lacking in a sufficient social
support network are more likely to have the worst physical
well-being and, thus, more likely to try unconventional ther-
apies. These findings are not dissimilar to other surveys in
women with breast cancer in which women with more se-
vere disease13,28–30 and younger age8,9,31–34 used more
CAM therapies. These results are in contrast to those of an
unpublished 1977 report of a Phase II clinical study that de-
termined that, although Essiac did not offer clinical benefit
to patients with cancer in terms of either survival or tumor
regression, there were significant subjective improvements
in symptom control and well-being.17,18,* Also, in 1997, an
abstract based on the Meeting Program Proceedings of the
American Society of Clinical Oncology identifying 59 pa-
tients who had taken Essiac in a retrospective review of 360
patients with breast, prostate, or gastrointestinal (GI) can-
cer. According to the subjective reports of these patients,
30% of patients on Essiac believed that it helped their qual-
ity of life.18 There are several possible explanations for the
differences in our study findings. First, the women in our
study may have been taking doses that were much lower
(around 1/4 cup per tea daily) than in other studies, and these
low doses may have been insufficient to produce a physio-
logic effect. Second, the manner in which quality of life was
assessed between the studies was different, with both of the
other studies using self-reports and not validated quality-of-
life scales. 
In our study, Essiac’s lack of effect on quality of life and
mood states may be a true finding, but Essiac could have
positive effects on tumor growth and reoccurrence measures
that our study was not designed to detect. There is limited
evidence from animal and in vitro studies showing antipro-
liferative effects of Essiac in cancer cell lines, although most
of the evidence shows no effect. A study of 8 mice injected
with human carcinoma cells revealed apparent tumor de-
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TABLE 4. RESULTS OF UNADJUSTED AND ADJUSTED ANALYSES FOR PROFILE OF MOOD STATES
Nonusers Essiac users
Subscales mean (STD) mean (STD) p value*1 Adjusted p value*2
Anxiety 3.9 (3.8) 4.4 (4.2) 0.46 0.41
Confusion 4.5 (2.7) 4.9 (3.1) 0.39 0.57
Depression 3.3 (3.8) 3.1 (4.0) 0.72 0.86
Anger 2.9 (3.4) 2.9 (4.0) 0.90 0.72
Fatigue 6.3 (7.3) 7.3 (5.1) 0.23 0.11
Vigor 11.5 (4.9) 11.6 (5.4) 0.83 0.51
*p values (1) are based on independent sample t-test comparing the mean of Essiac users to nonusers and (2) adjusted analyses are
based on multiple linear regressions with the mood subscales as outcomes, adjusted for age, marital status, income, educational status,
stage of disease, months since breast cancer diagnosis, and number of individuals in self-reported social network as reported by the
Yale Social Support Index.
STD, standard deviation.
TABLE 5. SUMMARY OF REGRESSION RESULTS OF PROFILE OF MOOD STATES (POMS) SUBSCALESa
Stage at Number of
Subscales Essiac use Age Income diagnosis supports Education
Anxiety 0.16 (0.22) 0.02 (0.01)* 0.09 (0.05) 0.02 (0.08) 0.02 (0.01)* 0.12 (0.08)
Confusion 0.07 (0.13) 0.02 (0.00)* 0.07 (0.03)** 0.03 (0.05) 0.00 (0.00) 0.00 (0.05)
Depression 0.04 (0.22) 0.03 (0.01)* 0.14 (0.05)** 0.16 (0.08)** 0.03 (0.01)* 0.07 (0.08)
Anger 0.07 (0.21) 0.03 (0.01)* 0.11 (0.05)** 0.02 (0.08) 0.01 (0.01)** 0.13 (0.08)
Fatigue 0.37 (0.23) 0.02 (0.01)* 0.13 (0.06)** 0.06 (0.08) 0.02 (0.01)* 0.07 (0.09)
Vigor 0.11 (0.17) 0.01 (0.01) 0.05 (0.04) 0.02 (0.06) 0.02 (0.01)* 0.16 (0.06)**
aTable entries are regression coefficients with standard errors (SE) in parentheses for the POMS subscales; outcomes are square root
of the subscale scores obtained from the survey for the subscales scores; all regression models are additionally adjusted for marriage
status (currently married or not), education level, and months since diagnosis. Negative regression coefficients indicate that the lower
the value (e.g., lower age, income) the worse the woman’s mood state; the opposite relationship is also true (e.g., lower stage/severity
at time of diagnosis the better the woman’s mood state).
*p value  0.01.
**p value  0.05.
*Caisse R. Essiac: A treatment for cancer: Report of patients
presented to The Royal Cancer Commission of Ontario (Canada).
Unpublished report; 1938.
generation after receiving Essiac. However, all observations
confirming tumor necrosis and cellular degradation in the
mice were narrative and not documented in terms of histo-
logic parameters.35 A recent in vitro study using Essiac and
Flor-Essence teas on human tumor cell lines (MCF7, MDA-
MB-468, Jurkat, and HL60 cells) demonstrated that both Es-
siac and Flor-Essence herbal teas demonstrated antiprolif-
erative and differentiation-inducing properties in vitro only
at high concentrations (1/10 and 1/100 dilutions) that are un-
likely to be obtained at doses being consumed by humans.36
In contrast, 6 immunotherapy and 2 chemotherapy tests on
2 dried and 1 liquid sample of Essiac provided by Ms. Caisse
to the Memorial Sloan-Kettering Cancer Center, New York,
NY (MSKCC) showed no in vivo activity.37 Researchers ad-
mit, however, that the negative results might have been
caused by the use of an inappropriate animal system and dif-
ficulties encountered in the preparation, administration, and
stability of Essiac.37 Furthermore, in another set of 17 stud-
ies conducted by MSKCC testing Resperin,™ a four-herb
Essiac blend, in animal leukemia and solid tumor test sys-
tems showed no antitumor activity.37 In a similar fashion,
the National Cancer Institute tested a liquid Essiac sample
in 1983 and found no antitumor activity in the mouse lym-
phocytic leukemia P388 tumor system.37
With more encouraging results, several human studies
have noted an improvement in tumor growth after individ-
uals took Essiac tea. In a study conducted by an Israeli mar-
keter, 20% showed tumor regression and 5% healed com-
pletely. This study, however, was not subjected to
peer-review.38 In a 1938 unpublished report, Caisse docu-
mented the progress of 24 cancer patients taking Essiac. All
patients experienced either complete or partial “cure,” but it
is unclear how these outcomes were measured.† In 1939, 49
of Caisse’s patients gave testimonials to the Canadian Can-
cer Commission on Caisse’s behalf. Of the eight patients
whose diagnoses were confirmed, the commission con-
cluded that only two of the four recoveries could be attrib-
uted to Essiac.39 In contrast, a Phase II clinical study deter-
mined that Essiac did not offer clinical benefit to cancer
patients in terms of either survival or tumor regression.17,18,*
In the early 1980s, the Canadian Department of National
Health and Welfare reviewed data from 86 patient histories
submitted from 74 of 150 physicians supervising the care of
patients on Essiac between 1978 and 1982.40 Essiac was
shown to have no benefit in 47 patients, 17 patients died, 8
were not evaluable based on the information provided, 1
demonstrated subjective improvement, 5 required fewer
analgesics, 4 had objective responses, and 4 remained sta-
ble with respect to disease progression.41,42 Unfortunately,
because the majority of these studies are unpublished, it is
difficult to assess the true effect of Essiac on tumor growth
and recurrence.
The women who used Essiac in our study are similar to
patients with breast cancer who have used CAM overall in
terms of demographic and clinical characteristics. Women
who used Essiac were significantly younger, were diagnosed
with breast cancer at a later stage, and are more likely to re-
ceive chemotherapy. Many other studies in patients with
breast cancer have found that younger age is associated with
higher prevalence of CAM use,8,9,31–34 and several other sur-
veys have found significant correlations between CAM use
and adjuvant chemotherapy,8,29,31,32,34 and stage of diagno-
sis,13,28–30 and presence of recurrence or metastasis of can-
cer.32,34 Women who were taking Essiac did differ from
overall CAM users in terms of educational attainment. In
contrast to other surveys in women with breast can-
cer,8,9,12,29,32–34,43 in which women with higher levels of ed-
ucation were more likely to use CAM, we did not observe
any significant difference in education between Essiac users
and nonusers.
Women who were taking Essiac also stated reasons that
were similar to those of women using other CAM therapies
for breast cancer. Most women in various surveys, includ-
ing ours, stated that they used CAM for some reason related
to helping their bodies to fight cancer or to boost their im-
mune systems,8,11,30,43 as well as to help improve their
chance of survival or to decrease the chance of a recurrence
of their cancer and restore hope for the future.8,11,44 Essiac
users also tend to get their information about Essiac from
the same sources as women with breast cancer get their in-
formation about other types of CAM: from friends and fam-
ily members.9,30
Women in our study reported only two adverse events in-
volving mild GI upset and an unpleasant taste. No women
reported any negative interactions with her conventional
breast-cancer treatment, whereas several women reported
positive benefits including decreased side-effects during ra-
diotherapy and chemotherapy that they attributed to taking
Essiac concurrently with their conventional treatments. The
lack of adverse events and negative interactions with adju-
vant cancer treatments in our study is confirmed by exist-
ing reports in the literature concerning Essiac lack of toxi-
city. Ever since evidence of 1 report of death and one report
of toxicity after Essiac tea injections18,19 in the 1930s, the
practice of injecting Essiac herbs has been considered un-
safe because of a potential for systemic toxicity. Instead,
Ms. Caisse introduced the blend of herbs used today, orally.
Preclinical and clinical evaluations of Flor-Essence, one of
the most popular brands of Essiac tea, have assessed acute
and chronic toxicity, determining no lethal dose level in
acute toxicity studies with albino mice and rats, nor any re-
nal or hepatic toxicity doses in chronic toxicity tests with
albino mice, rats (doses were 10 times greater than thera-
peutic dose at 15 mL/kg), and dogs (doses were five times
greater than therapeutic dose at 7.5 mL/kg)39 Several stud-
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tion Research & Manufacturing Association Research & Devel-
opment Institute of Medical & Aromatic Plants; 1996.
ies in humans have also reported no or very few adverse
events.18,38 When adverse events are reported, they are lim-
ited to minor cases of GI upset and unpleasant taste. Con-
sequently, it appears that Essiac is safe and relatively toler-
able in the doses recommended and consumed in our study.
Several limitations of our study need to be addressed. As
with any retrospective study, recall bias is a possible limi-
tation. However, the women in this study were asked to re-
call no more than 2 years into the past and some as little as
1 year. Consequently, we posit that only very detailed in-
formation such as the exact dose of Essiac would tend to be
inaccurately remembered. Another limitation of this study
was the low overall response rate and thus a low number of
Essiac users. The low response rate compared to a previous
survey in a similar population8 was a result of sending out
the survey in summer, when many women were away on
holiday, and the establishment of new privacy rules to pro-
tect patients. In addition, a switch from paper to electronic
records by the Ontario Cancer registry made it very diffi-
cult to contact potential study participant’s primary care
practitioners or oncologists and in association with the pri-
vacy laws, made clinic staff reluctant to release patient in-
formation.
Despite our low number of Essiac users, we were still
able to determine meaningful demographic and clinical dif-
ferences in these women, as well as establishing patterns of
Essiac dosing. For most of the FACT-B and POMS analy-
ses, we have about 40 Essiac users and between 424 and
447 nonusers available. A power calculation based on in-
dependent samples t-test demonstrate that one is able to de-
tect a standardized effect size of 0.46 in the standard devi-
ation scale with 80% power and group sizes of 40 and 424
(the smallest sizes available for any subscale analyses).
Thus, we are able to detect a medium effect size even with
a relatively small group of users. Although the general lack
of significance in the association of Essiac use with the HR-
QOL and mood states could be attributed to the group size
of users, the data nonetheless are indicative of a worsened
state of mind in the Essiac group. A larger sample size is
unlikely to change any underlying trend in the average dif-
ferences.
The worse QOL or mood scores in the Essiac users group
is perhaps attributable to the fact that this group consists of
younger women on an average who are diagnosed at an ad-
vanced stage of cancer, a subgroup of patients who are at a
worse state of mood or sense of well-being. Choice of Es-
siac being self-selected, it may be difficult to identify a di-
rect effect of Essiac use, be it positive or negative, on QOL
or mood states.
Despite our study’s limitations, this trial provides initial
information that future studies can build upon. The results
of this study suggest several future research directions. For
example, animal models could be used to investigate the
pharmacokinetics of Essiac and whether higher doses are
needed to reach significant concentrations in serum or tar-
get tissues. Animal studies could also be used to investigate
the effect of Essiac on tumor growth, metastasis, and reoc-
currence. Researchers could also use existing large prospec-
tive cohorts of women with breast cancer as another way of
investigating whether Essiac has an effect on tumor growth,
metastasis, and reoccurrence. In addition, a case series in
women with breast cancer using Essiac could help to pin-
point why certain women claim to have such dramatic re-
sults and why others do not. A case series could also help
to more clearly define meaningful outcomes that appear to
be changed by Essiac.
CONCLUSIONS
In conclusion, Essiac does not have a significant effect
on HR-QOL or mood states such as anxiety or vigor in
women with breast cancer, although Essiac at the doses
taken appears to be safe.
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